The DUS3L Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the human near-haploid HAP1 cell line. This product contains a heterogeneous pool of cells with targeted disruption of the DUS3L gene, providing a loss-of-function model suitable for functional studies. The polyclonal format preserves genetic diversity while ensuring effective gene knockout across the population, facilitating pooled assays and pharmacological evaluations.
HAP1 is a near-haploid chronic myeloid leukemia (CML) cell line originally derived from the KBM-7 line, harboring the BCR-ABL1 fusion oncogene. Its adherent fibroblast-like morphology and near-haploid karyotype make it ideal for recessive genetic screens, as only one allele per gene needs inactivation. This characteristic enables efficient dissection of oncogenic signaling and identification of synthetic lethal interactions in leukemia models.
DUS3L encodes an atypical dual-specificity phosphatase that negatively regulates MAPK signaling by dephosphorylating tyrosine and threonine residues on activated ERK1/2 (MAPK1/3). Acting downstream of RTK/RAS/RAF/MEK/ERK signaling, DUS3L is regulated by mitogenic stimuli and reactive oxygen species, and may interact with scaffolding proteins. By attenuating ERK1/2 phosphorylation, DUS3L dampens transcriptional responses and proliferation signals, serving as a key control point in tyrosine kinase cascades.
In HAP1 cells with BCR-ABL1-driven MAPK activation, DUS3L knockout amplifies ERK1/2 phosphorylation and proliferative signaling, potentially revealing vulnerabilities in kinase inhibitor sensitivity. The near-haploid background ensures complete gene disruption, enabling clear phenotypic analyses of DUS3L??s role in leukemia cell growth, survival, and drug response. This model is valuable for exploring feedback regulation in oncogenic MAPK signaling.
This knockout cell pool supports functional genomics screens, synthetic lethality studies, and MAPK pathway dissection using assays such as phospho-ERK Western blotting, RT-qPCR, MTT viability assays, flow cytometry, and colony formation. The polyclonal format is well-suited for pooled CRISPR screens and dose?Cresponse experiments with kinase inhibitors. For further details and ordering, contact Ascent Research.
